1. Home
  2. CRSP vs SOUN Comparison

CRSP vs SOUN Comparison

Compare CRSP & SOUN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • CRSP
  • SOUN
  • Stock Information
  • Founded
  • CRSP 2013
  • SOUN 2005
  • Country
  • CRSP Switzerland
  • SOUN United States
  • Employees
  • CRSP N/A
  • SOUN N/A
  • Industry
  • CRSP Biotechnology: Biological Products (No Diagnostic Substances)
  • SOUN EDP Services
  • Sector
  • CRSP Health Care
  • SOUN Technology
  • Exchange
  • CRSP Nasdaq
  • SOUN Nasdaq
  • Market Cap
  • CRSP 5.6B
  • SOUN 5.2B
  • IPO Year
  • CRSP 2016
  • SOUN N/A
  • Fundamental
  • Price
  • CRSP $52.57
  • SOUN $12.17
  • Analyst Decision
  • CRSP Buy
  • SOUN Buy
  • Analyst Count
  • CRSP 19
  • SOUN 7
  • Target Price
  • CRSP $71.94
  • SOUN $16.33
  • AVG Volume (30 Days)
  • CRSP 2.5M
  • SOUN 34.9M
  • Earning Date
  • CRSP 11-10-2025
  • SOUN 11-06-2025
  • Dividend Yield
  • CRSP N/A
  • SOUN N/A
  • EPS Growth
  • CRSP N/A
  • SOUN N/A
  • EPS
  • CRSP N/A
  • SOUN N/A
  • Revenue
  • CRSP $38,337,000.00
  • SOUN $148,404,000.00
  • Revenue This Year
  • CRSP N/A
  • SOUN $99.96
  • Revenue Next Year
  • CRSP $391.94
  • SOUN $28.92
  • P/E Ratio
  • CRSP N/A
  • SOUN N/A
  • Revenue Growth
  • CRSP N/A
  • SOUN 120.52
  • 52 Week Low
  • CRSP $30.04
  • SOUN $5.97
  • 52 Week High
  • CRSP $78.48
  • SOUN $24.98
  • Technical
  • Relative Strength Index (RSI)
  • CRSP 34.88
  • SOUN 29.65
  • Support Level
  • CRSP $52.42
  • SOUN $13.72
  • Resistance Level
  • CRSP $58.48
  • SOUN $14.98
  • Average True Range (ATR)
  • CRSP 3.56
  • SOUN 1.06
  • MACD
  • CRSP -1.14
  • SOUN -0.57
  • Stochastic Oscillator
  • CRSP 21.64
  • SOUN 9.05

About CRSP CRISPR Therapeutics AG

Crispr Therapeutics is a gene editing company focused on the development of Crispr/Cas9-based therapeutics. Crispr/Cas9 stands for clustered regularly interspaced short palindromic repeats (Crispr)/Crispr-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. The company is focused on using this technology to treat genetically defined diseases. Crispr's first approved drug is Casgevy, which was developed in collaboration with Vertex Pharmaceuticals and targets sickle-cell disease and transfusion-dependent beta-thalassemia, which have high unmet medical needs. The company is advancing a variety of gene editing programs in immuno-oncology, cardiovascular, and a stem cell-derived therapy to treat Type 1 diabetes.

About SOUN SoundHound AI Inc

SoundHound AI Inc is an innovator of conversational intelligence, offering an independent Voice AI platform that enables businesses across industries to deliver high-quality conversational experiences to customers. The company's voice AI delivers speed and accuracy in numerous languages to product creators and service providers across retail, financial services, healthcare, automotive, smart devices, and restaurants via groundbreaking AI-driven products like Smart Answering, Smart Ordering, Dynamic Drive-Thru, and Amelia AI Agents.

Share on Social Networks: